2850-36-4

Basic information

• Product Name: 1,3-DI-N-BUTYLXANTHINE
• Synonyms: LABOTEST-BB LT01148487;1,3-DI-N-BUTYLXANTHINE;1,3-DIBUTYLXANTHINE;1,3-dibutyl-7H-purine-2,6-dione;1,3-dibutyl-7H-purine-2,6-quinone;1,3-Dibutyl-1H-purine-2,6(3H,7H)-dione;1,3-Dibutyl-3,9-dihydro-1H-purine-2,6-dione;NSC 515484
• CAS NO: 2850-36-4
• Molecular Formula: C₁₃H₂₀N₄O₂
• Molecular Weight: 264.32
• Product Categories: Bases & Related Reagents;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 2850-36-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 474.7°Cat760mmHg
• Flash Point: 240.9°C
• Appearance: /
• Density: 1.179g/cm³
• Vapor Pressure: 3.54E-09mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 1,3-DI-N-BUTYLXANTHINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-DI-N-BUTYLXANTHINE(2850-36-4)
• EPA Substance Registry System: 1,3-DI-N-BUTYLXANTHINE(2850-36-4)

Safety Data

• Statements: 20/21/22
• Safety Statements: 22-36/37/39
• Hazardous Substances Data: 2850-36-4(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Denbefylline intermediate

InChI:InChI=1/C13H20N4O2/c1-3-5-7-16-11-10(14-9-15-11)12(18)17(13(16)19)8-6-4-2/h9H,3-8H2,1-2H3,(H,14,15)

Upstream product

• 64-18-6 formic acid 
• 52998-23-9 1,3-di-n-butyl-5,6-diamino-uracil 
• 132716-86-0 6-amino-1,3-di-n-butyl-5-nitroso-uracil 
• 41862-16-2 6-Amino-1,3-dibutylpyrimidine-2,4(1H,3H)-dione 
• 1792-17-2 N,N'-di-n-butylurea 
• 859442-33-4 N-(6-amino-1,3-dibutyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-formamide 
• 161419-76-7 N,N-di-n-butylurea 

Downstream Products

• 163259-15-2 C₃₉H₄₀N₄O₉ 
• 374593-68-7 7-((1aR,1bR,4aS,5R,5aS)-1a-Benzyloxymethyl-3,3-dimethyl-hexahydro-2,4-dioxa-cyclopropa[a]pentalen-5-yl)-1,3-dibutyl-3,7-dihydro-purine-2,6-dione 
• 263552-95-0 1,3-dibutyl-7-(4-hydroxyamino-benzenesulfonyl)-3,7-dihydro-purine-2,6-dione 
• 263552-81-4 1,3-dibutyl-7-(3-chloro-propane-1-sulfonyl)-3,7-dihydro-purine-2,6-dione 

Relevant articles and documents

Preparation of nucleoside uronamides as A3 adenosine receptor agonists.

The present invention provides N 6-benzyladenosine-5'-N-uronamide and related substituted compounds, particularly those containing substituents on the benzyl and/or uronamide groups, and modified xanthine ribosides, as well as pharmaceutical compositions containing such compounds. The present invention also provides a method of selectively activating an A 3 adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A 3 adenosine receptor a therapeutically effective amount of a compound which binds with the A. sub.3 receptor so as to stimulate an A 3 receptor-dependent response.

Structure-Activity Relationships of 1,3-Dialkylxanthine Derivatives at Rat A3 Adenosine Receptors

1,3-Dialkylxanthine analogues containing carboxylic acid and other charged groups on 8-position substituents were synthesized.These derivatives were examined for affinity in radioligand binding assays at rat brain A3 adenosine receptors stably